JP2016534104A - Mapキナーゼp38結合化合物 - Google Patents
Mapキナーゼp38結合化合物 Download PDFInfo
- Publication number
- JP2016534104A JP2016534104A JP2016533963A JP2016533963A JP2016534104A JP 2016534104 A JP2016534104 A JP 2016534104A JP 2016533963 A JP2016533963 A JP 2016533963A JP 2016533963 A JP2016533963 A JP 2016533963A JP 2016534104 A JP2016534104 A JP 2016534104A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound
- map kinase
- amino acid
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 195
- 102000043136 MAP kinase family Human genes 0.000 title description 3
- 108091054455 MAP kinase family Proteins 0.000 title description 3
- 108700012928 MAPK14 Proteins 0.000 claims abstract description 115
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims abstract description 109
- 150000001413 amino acids Chemical class 0.000 claims abstract description 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 45
- 230000004968 inflammatory condition Effects 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 34
- 108091000080 Phosphotransferase Proteins 0.000 claims description 32
- 102000020233 phosphotransferase Human genes 0.000 claims description 32
- -1 anti-inflammation Chemical class 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000008574 D-amino acids Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 238000007876 drug discovery Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 235000001014 amino acid Nutrition 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 13
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 11
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 11
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 9
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 238000003032 molecular docking Methods 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 108060006633 protein kinase Proteins 0.000 description 8
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000047918 Myelin Basic Human genes 0.000 description 7
- 101710107068 Myelin basic protein Proteins 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000976900 Homo sapiens Mitogen-activated protein kinase 14 Proteins 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 5
- 241000282465 Canis Species 0.000 description 5
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 5
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002875 fluorescence polarization Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000012867 alanine scanning Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 101150069380 JAK3 gene Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 101150073031 cdk2 gene Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SAUDSWFPPKSVMK-LBPRGKRZSA-N (2s)-2-(n-phenylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(O)=O)C1=CC=CC=C1 SAUDSWFPPKSVMK-LBPRGKRZSA-N 0.000 description 1
- ASVUOKGTAIPUBY-YFKPBYRVSA-N (2s)-2-(prop-2-enylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NCC=C ASVUOKGTAIPUBY-YFKPBYRVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyridine Chemical class C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100032311 Aurora kinase A Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 101100184273 Caenorhabditis elegans mnk-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 108010040923 D3 peptide Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 101001117143 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108091006012 Myc-tagged proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150020891 PRKCA gene Proteins 0.000 description 1
- 101150075026 PRKCB gene Proteins 0.000 description 1
- 101150073266 PRKCD gene Proteins 0.000 description 1
- 101150054473 PTK2 gene Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- 241000287433 Turdus Species 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 description 1
- 102100024150 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Human genes 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000006420 basal activation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 101150113535 chek1 gene Proteins 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000033 nuclear magnetic resonance titration Methods 0.000 description 1
- 229940063149 nutropin Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- AAGXHYSXWLDTFA-UHFFFAOYSA-N quinazolin-2-ylurea Chemical compound C1=CC=CC2=NC(NC(=O)N)=NC=C21 AAGXHYSXWLDTFA-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940053728 vitrasert Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
標準的な合成化学を用いて、次のペプチドを調製した。
1.BB2700 SRALLIFQKI(配列番号17)(N−アセチル化)
2.BB2702 HKSRALLIFQKIMWLRRQ(配列番号1)(N−アセチル化)
BB2702アミノ酸配列は、HKSRALLIFQKIMWLRRQ(配列番号1)であり、これはN−アセチル化されている。アラニン走査は、ペプチドの構造活性関係の構築を可能にする。活性ペプチドの各アミノ酸を、側鎖を有する最小アミノ酸であるアラニンによって順次置換し、その新たなペプチドの活性をテストすることによって、どのアミノ酸残基位置が活性にとって重要であるか、およびどの位置が重要でないかの図を構築できる。たとえば、我々が位置4のアルギニンをアラニンに置換するとき、我々は新たなペプチドがMAPキナーゼp38αを阻害する能力において大きな負の影響を知る。よって我々は、位置4のアルギニンがMAPキナーゼp38αへの結合およびその阻害におけるペプチドの重要な相互作用点であると結論付けることができる。ペプチドBB2702の18の位置の各々に対してこれを実行することによって、我々はp38αMAPキナーゼの阻害に必要なペプチドの主要残基部位の知識を構築する。このアプローチを用いて、結合のための配列中の主要な残基を示す。下の下線付き太字の位置にある残基は、MAPキナーゼp38αと高親和性で結合するために非常に重要であり、これらはMAPキナーゼp38αを阻害する能力を評価するためのアラニン走査実験および生化学アッセイにおける活性の評価によって判定されたものである。下線付き斜字体の位置にある残基は、重要であるが結合への影響が小さいものである。
材料
MKK6
E.coliにおいて発現されたGST融合タンパク質。ストック溶液12mg/ml。−80℃にて保存。(MKK6の基礎活性はP38αを活性化するために十分である。)
E.coliにおいて発現された6−his C−mycタグ付きタンパク質。ストック溶液10mg/ml。−80℃にて保存。
25mgを3.75mlキナーゼ緩衝液(およびβ−ΜΕ)に溶解する
ガラス蒸留水による1mMストック。−80℃にて保存。
1Mのストック水溶液。4℃にて保存。
20%および2%の水溶液の両方を調製。室温にて保存。
0.1mM EGTA(シグマE−4378)。50mM Tris/HCl pH7.4(シグマT−4003)。0.1mMオルトバナジン酸ナトリウム溶液(シグマS−6508)。4℃にて保存。使用直前に、緩衝液1ml当り1μlのβ−メルカプトエタノール(シグマM−7522)を加える。[0.038g(38mg)EGTA(シグマE−4378)。7.58gm TRIS/HCLプリセットPH7.4(シグマT−4003)。0.018g(18mg)オルトバナジン酸ナトリウム(シグマS−6508)。ガラス蒸留水にて1リットルにする。使用直前に、緩衝液1ml当り1μlのβ−メルカプトエタノール(シグマM−7522)を加える。4℃にて保存。]
DMSO用(コーニング社(Corning incorporated)(Costar(登録商標))3365(ポリプロピレン)。
アッセイプレート(コーニング社(Costar(登録商標))3596(ポリスチレン−平底、蓋付き)。
フィルタプレート(キャンバラ・パッカード(Cambarra Packard)6005174(および結合されたGF/Cフィルタ))。
酵素活性化
ヒトMAPキナーゼp38αを使用する前に、MKK6とともに30℃にて3時間インキュベートすることによって活性化する。活性化インキュベートは、550μlのキナーゼ緩衝液、75μl(1mM)のATP、75μl(100mM)のMgAc、50μl(10mg/ml)のP38α、および5μl(12mg/ml)のMKK6を含有する。この活性化インキュベートをアリコートして−20℃にて保存してもよい。
基準化合物はSB203580(IC50=0.025uM)である
*96ウェルプレート(ポリプロピレン)に入れる。
*第1行を除くすべての行に100μlのDMSOを入れる。
*DMSOとともに第1のウェルに50μlの化合物を入れる。
*混合しながらプレート全体に50μl。
*96ウェルプレート(ポリスチレン)に入れる。
*必要なすべての行に90μlのキナーゼ緩衝液を入れる。
*10μlの化合物希釈液(行3−1)(20μΜ−0.006μΜ(最終濃度)。
酵素活性化。
ヒトMAPキナーゼp38αを使用する前に、MKK6とともに30℃にて3時間インキュベートすることによって活性化する。活性化インキュベートは、550μlのキナーゼ緩衝液、75μl(1mM)のATP、75μl(100mM)のMgAc、50μl(10mg/ml)のP38α、および5μl(12mg/ml)のMKK6を含有する。この活性化インキュベートをアリコートして−20℃にて保存してもよい。
基準化合物はSB203580(IC50=0.025uM)である
Wt(mg)/MWt×100=添加すべきDMSOの量(ml))
*96ウェルプレート(ポリプロピレン)に入れる。
*第1行を除くすべての行に100μlのDMSOを入れる。
*DMSOとともに第1のウェルに50μlの化合物を入れる。
*混合しながらプレート全体に50μl。
*96ウェルプレート(ポリスチレン)に入れる。
*必要なすべての行に90μlのキナーゼ緩衝液を入れる。
*10μlの化合物希釈液(行5−12)(2.22μΜ−0.001μΜ(最終濃度))を移して混合する。
10μlを希釈プレート2からアッセイプレートに移す(2つ組で)(2%DMSO最終濃度)。
たとえばサイトカイン生成など、炎症反応の特定の局面をモデル化するために、Hela細胞を用いる。特に、リポ多糖(lipopolysaccharides:LPS)またはその他の炎症促進性刺激に応答した、TNFα、IL−1α、IL−1β、IL−6およびIL−8炎症性サイトカインの生成である。この生成は、MAPキナーゼp38α依存性または非依存性の手段を介するものであってもよい。この炎症シグナル伝達カスケードにおけるMAPキナーゼp38αの役割を探索するために、しばしばMAPキナーゼp38αの小分子阻害剤SB203580を使用する。図3は、Hela細胞におけるp38αの基礎リン酸化状態に対するBB2702の影響をみている。ホスホp38αはp38αの活性形であり、下流シグナル伝達を行って炎症性サイトカインの生成をもたらし得る。我々は(下の実施例8の)表2において、生化学アッセイにおいてBB2702がp38α活性化を阻害することを実証している。ここで我々は、BB2702があらゆる刺激の不在下で細胞モデルにおけるp38αリン酸化を抑制することを実証しており、つまりBB2702の存在下でp38α活性が低減することを実証している。このデータから、BB2702は基礎p38α活性の抑制をもたらすことを我々は結論付け得る。
MKK6によるMAPキナーゼp38αの活性化を阻害するためのBB2702(IC50=1nM)は、PRK2由来の疎水性PDK1相互作用フラグメント(PDK1−interacting fragment)または「PIF」、すなわちPDK1による基質キナーゼ活性化に関係するポケット結合モチーフ(バレンドラン(Balendran)ら(1999)カレント・バイオロジー(Curr.Biol.)9、393−402)と、配列モチーフ(LIFQKI)を共有している。PDK1の結晶構造(ビオンディ(Biondi)ら(2002)EMBOジャーナル(EMBO J.)21(16)、4219−28)において、対称性に関するPDK1分子のαGヘリックスは、触媒ドメインN末端ローブの「後ろ」側の疎水性モチーフ結合ポケットを占有しており、基質キナーゼとの分子間相互作用を模倣している。しかし、MAPキナーゼp38αは同等の疎水性モチーフ結合ポケットを欠いている。代わりにMAPキナーゼp38αのN末端ローブのこの領域は自身のC末端ヘリックスに占有されているため、このBB2702ペプチドのMAPキナーゼp38αへの強力な結合は、同等の相互作用の介在によるものではないと考えられる。
BB2702を、そのままで、またはMEF2A転写因子由来ペプチド(チャンら(2002)モレキュラー・セル(Mol.Cell.)9(6)、1241−9)(RKPDLRVVIPPSS)に加えて、均一に15N,2H−ラベルした6His−MAPキナーゼp38α(120μΜ)のサンプルに滴定した(サリバンら(2005)バイオケミストリー(Biochemistry)44(50)、16475−90)。各添加後に、1H−15N TROSY−HSQC NMRスペクトルを取得した。サリバンら(2005)に記載されるHCN三重共鳴クライオプローブを備えた600MHzバリアン・イノバ(Varian Inova)分光計において、298KにてNMR実験を記録した。
下の表1は、2つの選択されたペプチドの活性、およびそれらがMKK6またはMKK3の下のp38αのリン酸化すなわち活性化を阻害する能力を比較するものである。表1はさらに、コードされたペプチドが、活性化p38αがいくつかの基質をリン酸化する能力を阻害する能力を示す。表中のデータは、BB2702がMKK3ではなくMKK6によるp38αのリン酸化を阻害することを示し、さらにあらゆる活性p38αは直接阻害されて、MBPまたはMK2のリン酸化が妨げられることを示す。よってBB2702は、p38αの活性化の阻害と、活性p38αの不活性化との両方によって作用する。
図6は、THP−1細胞を用量依存性の態様でBB2702によって処置し、次いでLPS(リポ多糖)で刺激するときに、p38αの下流にあることが公知である炎症性サイトカインのTNFαの生成が有意に低減することを示す。このことは、容認されたTHP−1細胞炎症モデルにおいてp38αの介在する炎症シグナル伝達をBB2702が阻害できることを実証するものである。
Claims (27)
- アミノ酸配列HKSRALLIFQKIMWLRRQ(配列番号1)を含むか、または前記アミノ酸配列の7もしくはそれ以上のアミノ酸の部分を含むか、または前記アミノ酸配列もしくは前記アミノ酸配列の前記部分の1から5のアミノ酸が変更された変異体を含む化合物であって、前記化合物はMAPキナーゼp38αに結合する、化合物。
- 配列番号1の位置と比較したときに、位置4はRであり、位置9はFであり、かつ位置10はQである、請求項1に記載の化合物。
- 配列番号1の位置と比較したときに、位置2はK、RもしくはHであり、位置8はI、LもしくはMであり、位置13はM、IもしくはLであり、および/または、位置16はR、HもしくはKである、請求項1または請求項2に記載の化合物。
- 配列番号1の位置と比較したときに、Kであるか、位置8はIであるか、位置13はMであるか、または位置16はRである、請求項3に記載の化合物。
- 配列番号1の位置と比較したときに、位置2はKであり、位置8はIであり、位置13はMであり、かつ位置16はRである、請求項3に記載の化合物。
- 25000ダルトン未満の分子量を有する、請求項1〜5のいずれか一項に記載の化合物。
- 前記アミノ酸配列HKSRALLIFQKIMWLRRQ(配列番号1)か、または前記アミノ酸配列の7もしくはそれ以上のアミノ酸の部分からなっているか、または前記アミノ酸配列もしくは前記アミノ酸配列の前記部分の1から5のアミノ酸が変更された変異体を含む化合物であって、前記化合物はMAPキナーゼp38αに結合する、請求項1〜6のいずれか一項に記載の化合物。
- 前記アミノ酸配列HKSRALLIFQKIMWLRRQ(配列番号1)からなる、請求項1〜7のいずれか一項に記載の化合物。
- 以下のアミノ酸配列:HKSRALLIFQKIMWLRR(配列番号2)、HKSRALLIFQKIMWLR(配列番号3)、HKSRALLIFQKIMWL(配列番号4)、HKSRALLIFQKIMW(配列番号5)、KSRALLIFQKIMWLRRQ(配列番号6)、SRALLIFQKIMWLRRQ(配列番号7)、SRALLIFQKIM(配列番号8)、SRALLIFQ(配列番号9)、HALAIFQKIMW(配列番号10)、HKSRALAIFQKIMALRRQ(配列番号11)、AKSRALLIFQKIMWLRRQ(配列番号12)、HKSRAALIFQKIMWLRRQ(配列番号13)、HKSRALLIFQKIMWARRQ(配列番号14)、HKSRALLIFQKIMWLRAQ(配列番号15)、HKSRALLIFQKIMWLRRA(配列番号16)、またはSRALLIFQKI(配列番号17)からなる群より選択される、請求項1〜8のいずれか一項に記載の化合物。
- 複数のアミノ酸の間に少なくとも1つの非ペプチド結合を含有する、請求項1〜9のいずれか一項に記載の化合物。
- 少なくとも1つのD−アミノ酸残基を含有する、請求項1〜10のいずれか一項に記載の化合物。
- N末端および/またはC末端残基がブロックされている、請求項1〜11のいずれか一項に記載の化合物。
- 前記化合物は、別の部分に連結されたペプチドである、請求項1〜12のいずれか一項に記載の化合物。
- プロテアーゼ消化に対して実質的に耐性である、請求項1〜13のいずれか一項に記載の化合物。
- 請求項1〜14のいずれか一項に記載の化合物、および1つまたはそれ以上のさらなる治療化合物、たとえば抗炎症、抗細菌などの抗感染、または抗増殖化合物などを含む、組成物。
- 医薬に使用するための、請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物。
- 請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物と、薬学的に許容できる賦形剤または担体とを含む、医薬組成物。
- MAPキナーゼp38αを阻害するための方法であって、前記方法は、前記キナーゼと、請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物とを接触させるステップを含む、方法。
- MAPキナーゼp38αを阻害するための、請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物の使用。
- 個体における炎症状態を処置するための方法であって、前記方法は、請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物を個体に投与するステップを含む、方法。
- 個体における炎症状態の処置に使用するための、請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物。
- 個体における炎症状態を処置するための薬物の製造における、請求項1〜14のいずれか一項に記載の化合物、または請求項15に記載の組成物の使用。
- MAPキナーゼp38αに結合する分子を同定するための方法であって、前記方法は、請求項1〜14のいずれか一項に記載の化合物がMAPキナーゼp38αに結合する位置において、前記分子がMAPキナーゼp38αに結合するかどうかを判定するステップを含む、方法。
- 同定された前記分子を薬学的に許容できる組成物に調合するステップをさらに含む、請求項23に記載の方法。
- 医薬組成物を作製する方法であって、請求項23に記載の方法を実行するステップと、同定された前記分子を薬学的に許容できる担体と混合するステップとを含む、方法。
- MAPキナーゼp38αに結合する、本明細書に開示される任意の新規ペプチド。
- 個体における炎症状態の処置に使用するための、MAPキナーゼp38αに結合する、本明細書に開示される任意の新規ペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1314610.5A GB201314610D0 (en) | 2013-08-15 | 2013-08-15 | Compounds and their uses |
GB1314610.5 | 2013-08-15 | ||
PCT/GB2014/052514 WO2015022549A1 (en) | 2013-08-15 | 2014-08-15 | Map kinase p38 binding compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016534104A true JP2016534104A (ja) | 2016-11-04 |
JP6566947B2 JP6566947B2 (ja) | 2019-08-28 |
Family
ID=49301752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533963A Active JP6566947B2 (ja) | 2013-08-15 | 2014-08-15 | Mapキナーゼp38結合化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10293024B2 (ja) |
EP (1) | EP3033094B1 (ja) |
JP (1) | JP6566947B2 (ja) |
CN (1) | CN105705158A (ja) |
ES (1) | ES2761599T3 (ja) |
GB (1) | GB201314610D0 (ja) |
WO (1) | WO2015022549A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107556368B (zh) * | 2017-07-17 | 2019-06-25 | 北京博肽未名生物技术有限公司 | 一种蛋白激酶多肽抑制剂 |
GB202217153D0 (en) * | 2022-11-16 | 2022-12-28 | Carocell Bio Ltd | Peptides |
CN116282419B (zh) * | 2023-03-17 | 2023-11-28 | 成都速康畜牧科技有限公司 | 一种自动加药器及其加药方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911958A (zh) * | 2006-08-04 | 2007-02-14 | 北京大学 | 一种抑制p38激酶活性的多肽及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0749475A4 (en) * | 1992-08-26 | 1997-05-07 | Harvard College | USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY |
CN1307123A (zh) * | 2000-01-26 | 2001-08-08 | 上海博道基因技术有限公司 | 一种新的多肽——GTP酶的Rho家族活性位点27和编码这种多肽的多核苷酸 |
EP1390468A4 (en) * | 2001-04-23 | 2004-09-22 | Elitra Pharmaceuticals Inc | IDENTIFICATION OF ESSENTIAL GENES OF ASPERGILLUS FUMIGATUS AND METHOD OF USE |
WO2004069191A2 (en) * | 2003-02-03 | 2004-08-19 | Senomyx Inc. | Identification of t1r and t2r modulators |
CA2533803A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
US7906149B2 (en) * | 2007-05-25 | 2011-03-15 | Boval Company, L.P. | Method for treating allergic dermatitis |
ES2547229T3 (es) | 2007-08-07 | 2015-10-02 | Purdue Research Foundation | Inhibidores de cinasa y usos de los mismos |
US8575305B2 (en) * | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
WO2011126882A2 (en) | 2010-03-30 | 2011-10-13 | American Type Culture Collection | Therapeutic peptides and their derivatives and therapeutic uses thereof |
WO2012037397A2 (en) * | 2010-09-15 | 2012-03-22 | Stc.Unm | Step-derived peptide for brain injury treatment |
WO2012066376A1 (en) * | 2010-11-18 | 2012-05-24 | Centre National De La Recherche Scientifique - Cnrs - | Inhibitors of apoptosis and uses thereof |
-
2013
- 2013-08-15 GB GBGB1314610.5A patent/GB201314610D0/en not_active Ceased
-
2014
- 2014-08-15 WO PCT/GB2014/052514 patent/WO2015022549A1/en active Application Filing
- 2014-08-15 JP JP2016533963A patent/JP6566947B2/ja active Active
- 2014-08-15 EP EP14756109.6A patent/EP3033094B1/en active Active
- 2014-08-15 ES ES14756109T patent/ES2761599T3/es active Active
- 2014-08-15 CN CN201480045406.XA patent/CN105705158A/zh active Pending
- 2014-08-15 US US14/911,658 patent/US10293024B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911958A (zh) * | 2006-08-04 | 2007-02-14 | 北京大学 | 一种抑制p38激酶活性的多肽及其应用 |
Non-Patent Citations (2)
Title |
---|
J FIRST MIL MED UNIV, vol. Vol. 23, No. 11, JPN6018029464, November 2003 (2003-11-01), pages p. 1131-1133 * |
MOLECULAR CELL, vol. Vol. 9, No. 6, JPN6018029463, June 2002 (2002-06-01), pages p. 1241-1249 * |
Also Published As
Publication number | Publication date |
---|---|
US10293024B2 (en) | 2019-05-21 |
WO2015022549A1 (en) | 2015-02-19 |
EP3033094A1 (en) | 2016-06-22 |
ES2761599T3 (es) | 2020-05-20 |
JP6566947B2 (ja) | 2019-08-28 |
EP3033094B1 (en) | 2019-11-06 |
CN105705158A (zh) | 2016-06-22 |
US20160193281A1 (en) | 2016-07-07 |
GB201314610D0 (en) | 2013-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005279308B2 (en) | Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use | |
Flygare et al. | Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152) | |
Finch et al. | Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a | |
US20020147306A1 (en) | Peptides that modulate the interaction of B class ephrins and PDZ domains | |
JP2008540339A (ja) | Nogoレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法 | |
US20240132544A1 (en) | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides | |
KR20140142293A (ko) | 조작된 입체형태적으로-안정화된 단백질 | |
JP6566947B2 (ja) | Mapキナーゼp38結合化合物 | |
Hegedüs et al. | Identification of β-strand mediated protein–protein interaction inhibitors using ligand-directed fragment ligation | |
Haugaard-Kedstrom et al. | A high-affinity peptide ligand targeting syntenin inhibits glioblastoma | |
Rastelli et al. | A KDR-binding peptide (ST100, 059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo | |
Calugi et al. | Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein | |
US11369662B2 (en) | Methods of treating inflammation with monomeric CXCL12 peptide | |
Scognamiglio et al. | Discovery of Small Peptide Antagonists of PED/PEA15–D4α Interaction from Simplified Combinatorial Libraries | |
US12098175B2 (en) | Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof | |
US20220153792A1 (en) | Peptide Inhibitors Targeting The CXCL12/HMGB1 Interaction And Uses Thereof | |
WO2024105410A2 (en) | Peptides | |
US20120178682A1 (en) | GB1 Peptidic Compounds and Methods for Making and Using the Same | |
Pepanian et al. | In-depth characterization of Gαs protein activity by probing different guanine nucleotides | |
Moerke | Structural and chemical genetic studies of eukaryotic translation initiation factors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170815 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190702 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190730 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6566947 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |